Inhibitory effect of idebenone (CV-2619), a novel compound, on vascular lesions in hypertensive rats.
The effects of a novel compound, 6-(10-hydroxydecyl)-2,3-dimethoxy-5-methyl-1,4-benzoquinone (idebenone, CV-2619), on cerebral and renal vascular changes were examined in stroke-prone spontaneously hypertensive rats (SHRSP) and in rats with experimentally induced hypertension. CV-2619 (35 mg/kg/day, p.o.) significantly inhibited the onset of cerebrovascular lesions (stroke) and the elevation of blood pressure in SHRSP with mild hypertension. A higher dose (2 X 50 mg/kg/day, p.o.) clearly delayed the onset of both stroke and proteinuria without any effect on the blood pressure in SHRSP with severe hypertension. In DOCA-salt hypertensive rats, CV-2619 (2 X 5 or 2 X 25 mg/kg/day, p.o.) dose-dependently inhibited decreases in body weight and water balance and the development of cerebral and renal vascular changes. These results suggest that CV-2619 inhibits the development of stroke and renal vascular lesions in hypertensive rats.
D000818:Animals; D016227:Benzoquinones; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D001921:Brain / Q000473:pathology; D002561:Cerebrovascular Disorders / Q000473:pathology / Q000503:physiopathology / Q000517:prevention & control; D006973:Hypertension / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology*; D007668:Kidney / Q000473:pathology; D008297:Male; D011809:Quinones / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D011918:Rats, Inbred SHR; D011921:Rats, Inbred WKY; D013997:Time Factors; D014451:Ubiquinone / Q000031:analogs & derivatives; D014882:Water-Electrolyte Balance / Q000187:drug effects
D016227:Benzoquinones; D011809:Quinones; D014451:Ubiquinone; C036619:idebenone